Abstract | PURPOSE: METHODS: The patient was a 61-year-old man who presented with dendritic keratitis in his left eye. After recognizing his difficulty in using eye ointment, we prescribed oral VACV 500 mg tablets twice daily for 7 days. We also describe our experiments with orally administered VACV in a mouse model of this disease. In this study, 143 Balb/c mice were inoculated with herpes simplex virus type 1 (HSV)-1 in each eye and treated with oral VACV 50 or 100 mg/kg twice daily, oral acyclovir (ACV) 50 mg/kg 5 times/d, 3% ACV eye ointment (ACV-O) 5 times/d, 3% ACV eye drops 5 times/d, or control for 5 days. RESULTS: After 7 days, the patient's lesion was observed healed. Corrected left visual acuity was also improved, and HSV DNA was below detectable level. In the mouse study, slit-lamp examination on days 3, 4, 5, and 7 revealed that all 5 ACV and VACV treatment groups were significantly more effective in improving symptoms of herpetic epithelial keratitis versus control (P < 0.05). Moreover, VACV 100 mg/kg was superior to other treatments. Viral titers in mouse eyeball and trigeminal ganglia were lowest in the VACV 100 mg/kg group versus other treatment groups. CONCLUSION: Our case example suggests that when frequent application, blurred vision, and foreign body sensation after ACV-O application cause difficulty for patients to follow treatment, oral VACV might be an effective and safe option for patients with herpetic keratitis.
|
Authors | Shiro Higaki, Motoki Itahashi, Tatsunori Deai, Masahiko Fukuda, Yoshikazu Shimomura |
Journal | Cornea
(Cornea)
Vol. 25
Issue 10 Suppl 1
Pg. S64-7
(Dec 2006)
ISSN: 0277-3740 [Print] United States |
PMID | 17001196
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antiviral Agents
- DNA, Viral
- Prodrugs
- Valine
- Valacyclovir
- Acyclovir
|
Topics |
- Acyclovir
(analogs & derivatives, therapeutic use)
- Administration, Oral
- Animals
- Antiviral Agents
(therapeutic use)
- Cornea
(virology)
- DNA, Viral
(analysis)
- Disease Models, Animal
- Gene Dosage
- Herpesvirus 1, Human
(genetics)
- Humans
- Keratitis, Dendritic
(drug therapy, virology)
- Keratitis, Herpetic
(drug therapy)
- Male
- Mice
- Mice, Inbred BALB C
- Middle Aged
- Polymerase Chain Reaction
- Prodrugs
(therapeutic use)
- Valacyclovir
- Valine
(analogs & derivatives, therapeutic use)
|